These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 37217351)

  • 21. Validation of a Nomogram to Predict Recurrence in Patients with Mucinous Neoplasms of the Appendix with Peritoneal Dissemination After Cytoreductive Surgery and HIPEC.
    Martín Román L; Lozano P; Baratti D; Kusamura S; Deraco M; Vásquez W; González Bayón L
    Ann Surg Oncol; 2022 Nov; 29(12):7553-7563. PubMed ID: 35876926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peritoneal carcinomatosis of colorectal origin treated by cytoreductive surgery and hyperthermic intraoperative peritoneal chemotherapy at the Bulovka University Hospital.
    Bartoška P; Antoš F; Vobořil R; Vítek P; Marx J; Holečková P; Novotný M; Kengbaeva M
    Rozhl Chir; 2021; 100(10):490-496. PubMed ID: 35021840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of Stable Lung Colorectal Metastases on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Pantelis A; Ben-Yaacov A; Adileh M; Schtrechman G; Shacham-Shmueli E; Boursi B; Margalit O; Halpern N; Mor E; Assaf D; Maximiliano K; Nissan A; Laks S
    J Gastrointest Surg; 2022 Aug; 26(8):1724-1731. PubMed ID: 35768716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
    Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
    World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcomes of elderly patients with peritoneal metastases of colorectal origin after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Weksler Y; Hoffman A; Green E; Kyzer M; Nevo N; Gerstenhaber F; Greenberg R; Klausner JM; Gutman M; Lahat G; Berger Y; Geva R; Nizri E
    Surg Oncol; 2022 Sep; 44():101848. PubMed ID: 36126349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An International Registry of Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Mercier F; Passot G; Bonnot PE; Cashin P; Ceelen W; Decullier E; Villeneuve L; Walter T; Levine EA; Glehen O; ;
    World J Surg; 2022 Jun; 46(6):1336-1343. PubMed ID: 35286418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients.
    Zhang J; Li XB; Ji ZH; Ma R; Bai WP; Li Y
    Biomed Res Int; 2021; 2021():5533134. PubMed ID: 34258265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
    Tabrizian P; Shrager B; Jibara G; Yang MJ; Romanoff A; Hiotis S; Sarpel U; Labow DM
    J Gastrointest Surg; 2014 May; 18(5):1024-31. PubMed ID: 24577736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies-experience from a tertiary care center in Germany.
    Reese M; Eichelmann AK; Nowacki TM; Pascher A; Sporn JC
    Langenbecks Arch Surg; 2024 Apr; 409(1):113. PubMed ID: 38589714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreductive Surgery and Hyperthermic Peritoneal Chemotherapy in Appendiceal and Colorectal Cancer: Outcomes and Survival.
    Djadou TM; Poh KS; Yellinek S; Fayazzadeh H; El-Hayek K; Simpfendorfer CH; DaSilva G; Wexner SD
    Am Surg; 2023 Dec; 89(12):5757-5767. PubMed ID: 37155318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still beneficial in patients diagnosed with colorectal peritoneal metastasis who underwent palliative chemotherapy?
    Cho HJ; Kim JW; Kim WR
    Asian J Surg; 2024 Jan; 47(1):296-302. PubMed ID: 37648541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extremely high peritoneal cancer index in colorectal peritoneal metastases demonstrates safety and overall survival benefit in selected patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy.
    Ben-Yaacov A; Levine O; Schtrechman G; Adileh M; Beller T; Boursi B; Halpern N; Goldstein A; Ben-Yakov G; Nissan A; Laks S
    World J Surg; 2024 Apr; 48(4):871-878. PubMed ID: 38686748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience.
    Valenzuela CD; Levine EA; Mangieri CW; Gawdi R; Moaven O; Russell G; Lundy ME; Perry KC; Votanopoulos KI; Shen P
    Ann Surg Oncol; 2022 Jun; 29(6):3436-3445. PubMed ID: 35286531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients.
    Yan G; Zhang K; Yan L; Zhang Y
    World J Surg Oncol; 2024 May; 22(1):144. PubMed ID: 38822337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis.
    Hajjar R; Mercier F; Passot G; Pasquer A; Gelli M; Levine EA; Villeneuve L; Poncet G; Walter T; Glehen O
    Eur J Surg Oncol; 2022 Jul; 48(7):1626-1630. PubMed ID: 35418324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer.
    Di Giorgio A; Santullo F; Attalla El Halabieh M; Lodoli C; Abatini C; Calegari MA; Martini M; Rotolo S; Pacelli F
    J Gastrointest Surg; 2021 Oct; 25(10):2649-2659. PubMed ID: 34244953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study.
    Turner KM; Morris MC; Delman AM; Hanseman D; Johnston FM; Greer J; Walle KV; Abbott DE; Raoof M; Grotz TE; Fournier K; Dineen S; Veerapong J; Maduekwe U; Kothari A; Staley CA; Maithel SK; Lambert LA; Kim AC; Cloyd JM; Wilson GC; Sussman JJ; Ahmad SA; Patel SH
    J Gastrointest Surg; 2022 Dec; 26(12):2569-2578. PubMed ID: 36258061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment and Survival Outcomes for Patients with Colorectal Peritoneal Metastases Deemed Ineligible for Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Results of a Retrospective Study.
    Dietz MV; Ziekman MJ; van Kooten JP; Brandt-Kerkhof ARM; van Meerten E; Verhoef C; Madsen EVE
    Ann Surg Oncol; 2023 Apr; 30(4):2048-2056. PubMed ID: 36566258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Patients Undergoing CRS/HIPEC for Colorectal Adenocarcinoma with Peritoneal Metastases, Presence of Ascites on Computed Tomography Imaging is not a Prognostic Marker for Survival.
    Said I; Ubink I; Ewalds RSG; Arkesteijn JGT; Verheul HMW; de Wilt JHW; Dekker HM; Bremers AJA; de Reuver PR
    Ann Surg Oncol; 2022 Aug; 29(8):5256-5262. PubMed ID: 35430666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic Colorectal Cancer Treated with Combined Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Predictive Factors for Early Recurrence.
    Grange R; Rousset P; Williet N; Guesnon M; Milot L; Passot G; Phelip JM; Le Roy B; Glehen O; Kepenekian V
    Ann Surg Oncol; 2024 Apr; 31(4):2378-2390. PubMed ID: 38170409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.